Bone Mineral Density Changes in Multiple Endocrine Neoplasia Type 1: A Systematic Review and Meta-Analysis of Prevalence and Parathyroidectomy Outcomes

Document Type : SYSTEMATIC REVIEW

Authors

1 Clinical Research Development Unit, Ghaem Hospital, Mashhad University of Medical Sciences, Mashhad, Iran

2 Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

10.22038/abjs.2025.82946.3775

Abstract

Objectives: This study aimed to analyze the prevalence of osteopenia and osteoporosis in MEN1-related primary hyperparathyroidism (PHPT), examine the impact of parathyroidectomy (PTX) on bone metabolic outcomes, and compare bone density metrics between sporadic and MEN1-related PHPT.
Methods: A systematic review and meta-analysis were conducted in accordance with the guidelines for Meta-Analyses and Systematic Reviews of Observational Studies (MOOSE). We searched PubMed, Web of Science, and Scopus up to June 2024, subsequently screening the articles to identify relevant research. Studies focusing on bone mineral density (BMD), T and Z-scores in patients with MEN1-related conditions were included. Meta-analyses were conducted using random-effects models.
Results: From the initial 2,563 articles, 15 studies were included in the meta-analysis. The pooled prevalence of osteoporosis and osteopenia in patients with MEN1-related PHPT was 45.2% (95% CI: 39.1-51.4%; I2: 16.7%) and 53.3% (95% CI: 44.4-62.0%; I2: 36.15%), respectively. PTX showed no significant impact on BMD in MEN1-related PHPT patients at the lumbar spine (mean difference: -0.054; P-value = 0.092; I2: 0.86%) or femoral neck (mean difference: -0.025; P-value = 0.219; I2: 0.47%). Comparisons of bone density metrics showed that MEN1-related PHPT patients had significantly lower Z-scores at the lumbar spine (mean difference: -0.676; P-value < 0.001; I2: 41.86%), total hip (mean difference: -0.629; P < 0.001; I2: 23.4%), and femoral neck (mean difference: -0.516; P < 0.001; I2 = 38.82%) compared to patients with sporadic PHPT.
Conclusion: Patients with MEN1-related PHPT exhibited a high prevalence of osteopenia and osteoporosis, along with lower BMD metrics compared to those with sporadic PHPT. PTX was not associated with significant changes in BMD among MEN1-related PHPT patients.
        Level of evidence: V
Objectives: This study aimed to analyze the prevalence of osteopenia and osteoporosis in MEN1-related primary hyperparathyroidism (PHPT), examine the impact of parathyroidectomy (PTX) on bone metabolic outcomes, and compare bone density metrics between sporadic and MEN1-related PHPT.
Methods: A systematic review and meta-analysis were conducted in accordance with the guidelines for Meta-Analyses and Systematic Reviews of Observational Studies (MOOSE). We searched PubMed, Web of Science, and Scopus up to June 2024, subsequently screening the articles to identify relevant research. Studies focusing on bone mineral density (BMD), T and Z-scores in patients with MEN1-related conditions were included. Meta-analyses were conducted using random-effects models.
Results: From the initial 2,563 articles, 15 studies were included in the meta-analysis. The pooled prevalence of osteoporosis and osteopenia in patients with MEN1-related PHPT was 45.2% (95% CI: 39.1-51.4%; I2: 16.7%) and 53.3% (95% CI: 44.4-62.0%; I2: 36.15%), respectively. PTX showed no significant impact on BMD in MEN1-related PHPT patients at the lumbar spine (mean difference: -0.054; P-value = 0.092; I2: 0.86%) or femoral neck (mean difference: -0.025; P-value = 0.219; I2: 0.47%). Comparisons of bone density metrics showed that MEN1-related PHPT patients had significantly lower Z-scores at the lumbar spine (mean difference: -0.676; P-value < 0.001; I2: 41.86%), total hip (mean difference: -0.629; P < 0.001; I2: 23.4%), and femoral neck (mean difference: -0.516; P < 0.001; I2 = 38.82%) compared to patients with sporadic PHPT.
Conclusion: Patients with MEN1-related PHPT exhibited a high prevalence of osteopenia and osteoporosis, along with lower BMD metrics compared to those with sporadic PHPT. PTX was not associated with significant changes in BMD among MEN1-related PHPT patients.
        Level of evidence: V

Keywords

Main Subjects

References

  1. Walls GV. Multiple endocrine neoplasia (MEN) syndromes. Semin Pediatr Surg. 2014; 23(2):96-101. doi:10.1053/j.sempedsurg.2014.03.008.
  2. McDonnell JE, Gild ML, Clifton-Bligh RJ, Robinson BG. Multiple endocrine neoplasia: an update. Intern Med J. 2019; 49(8):954-961. doi:10.1111/imj.14394.
  3. Brandi ML, Agarwal SK, Perrier ND, Lines KE, Valk GD, Thakker RV. Multiple Endocrine Neoplasia Type 1: Latest Insights. Endocr Rev. 2021; 42(2):133-170. doi:10.1210/endrev/bnaa031.
  4. Norton JA, Krampitz G, Jensen RT. Multiple Endocrine Neoplasia: Genetics and Clinical Management. Surg Oncol Clin N Am. 2015; 24(4):795-832. doi:10.1016/j.soc.2015.06.008.
  5. Wang W, Nie M, Jiang Y, et al. Impaired geometry, volumetric density, and microstructure of cortical and trabecular bone assessed by HR-pQCT in both sporadic and MEN1-related primary hyperparathyroidism. Osteoporos Int. 2020; 31(1):165-173. doi:10.1007/s00198-019-05186-1.
  6. Silva AM, Vodopivec D, Christakis I, et al. Operative intervention for primary hyperparathyroidism offers greater bone recovery in patients with sporadic disease than in those with multiple endocrine neoplasia type 1-related hyperparathyroidism. Surgery. 2017; 161(1):107-115. doi:10.1016/j.surg.2016.06.065.

 

  1. Burgess JR, David R, Greenaway TM, Parameswaran V, Shepherd JJ. Osteoporosis in multiple endocrine neoplasia type 1: severity, clinical significance, relationship to primary hyperparathyroidism, and response to parathyroidectomy. Arch Surg. 1999; 134(10):1119-23. doi:10.1001/archsurg.134.10.1119.
  2. Slouma M, Abbes M, Dhahri R, et al. Multiple endocrine neoplasia type 1 revealed by a hip pathologic fracture. Clin Rheumatol. 2021; 40(2):775-782. doi:10.1007/s10067-020-05281-3.
  3. Pieterman CR, van Leeuwaarde RS, van den Broek MF, van Nesselrooij BP, Valk GD. Multiple endocrine neoplasia type 1. In: Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000.
  4. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Jama. 2000; 283(15):2008-2012. doi: 10.1001/jama.283.15.2008.
  5. Wells GA, Shea B, O’Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses; 2000.
  6. Eller-Vainicher C, Chiodini I, Battista C, et al. Sporadic and MEN1-related primary hyperparathyroidism: differences in clinical expression and severity. J Bone Miner Res. 2009; 24(8):1404-10. doi:10.1359/jbmr.090304.
  7. Keutgen XM, Nilubol N, Agarwal S, et al. Reoperative Surgery in Patients with Multiple Endocrine Neoplasia Type 1 Associated Primary Hyperparathyroidism. Ann Surg Oncol. 2016;23(Suppl 5):701-707. doi:10.1245/s10434-016-5467-x.
  8. Kong J, Wang O, Nie M, et al. Clinical and Genetic Analysis of Multiple Endocrine Neoplasia Type 1-Related Primary Hyperparathyroidism in Chinese. PLoS One. 2016; 11(11):e0166634. doi:10.1371/journal.pone.0166634.
  9. Marini F, Giusti F, Cioppi F, et al. Bone and Mineral Metabolism Phenotypes in MEN1-Related and Sporadic Primary Hyperparathyroidism, before and after Parathyroidectomy. Cells. 2021; 10(8) doi: 10.3390/cells10081895.
  10. Moyes VJ, Monson JP, Chew SL, Akker SA. Clinical Use of Cinacalcet in MEN1 Hyperparathyroidism. Int J Endocrinol. 2010; 2010:906163. doi:10.1155/2010/906163.
  11. Norton JA, Venzon DJ, Berna MJ, et al. Prospective study of surgery for primary hyperparathyroidism (HPT) in multiple endocrine neoplasia-type 1 and Zollinger-Ellison syndrome: long-term outcome of a more virulent form of HPT. Ann Surg. 2008; 247(3):501-10. doi:10.1097/SLA.0b013e31815efda5.
  12. Song A, Chen R, Guan W, et al. Trabecular Bone Score as a More Sensitive Tool to Evaluate Bone Involvement in MEN1-related Primary Hyperparathyroidism. J Clin Endocrinol Metab. 2023; 109(1):135-142. doi:10.1210/clinem/dgad460.
  13. Kann PH, Bartsch D, Langer P, et al. Peripheral bone mineral density in correlation to disease-related predisposing conditions in patients with multiple endocrine neoplasia type 1. J Endocrinol Invest. 2012; 35(6):573-9. doi:10.3275/7880.
  14. Coutinho FL, Lourenco DM, Jr., Toledo RA, Montenegro FL, Correia-Deur JE, Toledo SP. Bone mineral density analysis in patients with primary hyperparathyroidism associated with multiple endocrine neoplasia type 1 after total parathyroidectomy. Clin Endocrinol (Oxf). 2010; 72(4):462-8. doi:10.1111/j.1365-2265.2009.03672.x.
  15. Lourenco DM, Jr., Toledo RA, Mackowiak, II, et al. Multiple endocrine neoplasia type 1 in Brazil: MEN1 founding mutation, clinical features, and bone mineral density profile. Eur J Endocrinol. 2008; 159(3):259-74. doi:10.1530/EJE-08-0153.
  16. Lourenco DMJ, Coutinho FL, Toledo RA, Montenegro FLM, Correia-Deur JEM, Toledo SPA. Early-Onset, Progressive, Frequent, Extensive and Severe Bone Mineral and Urolithiasis-Related Renal Complications in Multiple Endocrine Neoplasia Type 1-Related Primary Hyperparathyroidism. J Bone Miner Res. 2010; 31(3) doi:10.1002/jbmr.125.
  17. Mathew UE, Goyal A, Upadhyay AD, et al. Clinical profile and treatment outcomes among patients with sporadic and multiple endocrine neoplasia syndrome-related primary hyperparathyroidism. Clin Endocrinol (Oxf). 2023; 99(5):449-458. doi:10.1111/cen.14945.
  18. Al-Salameh A, Cadiot G, Calender A, Goudet P, Chanson P. Clinical aspects of multiple endocrine neoplasia type 1. Nat Rev Endocrinol. 2021; 17(4):207-224. doi:10.1038/s41574-021-00468-3.
  19. Thakker RV, Newey PJ, Walls GV, et al. Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J Clin Endocrinol Metab. 2012; 97(9):2990-3011. doi:10.1210/jc.2012-1230.
  20. Lambert LA, Shapiro SE, Lee JE, et al. Surgical treatment of hyperparathyroidism in patients with multiple endocrine neoplasia type 1. Arch Surg. 2005; 140(4):374-82. doi:10.1001/archsurg.140.4.374.
  21. Figueiredo AA, Saramago A, Cavaco BM, Simões-Pereira J, Leite V. Familial parathyroid tumours—comparison of clinical profiles between syndromes. J Endocrinol Invest. 2023; 46(9):1799-1806. doi:10.1007/s40618-023-02032-4.
  22. Brandi ML, Gagel RF, Angeli A, et al. Consensus: guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab. 2001; 86(12):5658-5671. doi:10.1210/jcem.86.12.8070.
  23. Siperstein A, Berber E, Barbosa GF, et al. Predicting the success of limited exploration for primary hyperparathyroidism using ultrasound, sestamibi, and intraoperative parathyroid hormone: analysis of 1158 cases. Ann Surg. 2008; 248(3):420-8. doi:10.1097/SLA.0b013e3181859f71.
  24. Alevizaki M, Saltiki K. Primary Hyperparathyroidism in MEN2 Syndromes. Recent Results Cancer Res. 2015; 204:179-86. doi:10.1007/978-3-319-22542-5_8.

 

 

 

 

 

The Archives of Bone and Joint Surgery
Volume 13, Issue 3
March 2025
Pages 125-133

Files

History

  • Receive Date: 01 October 2024
  • Revise Date: 17 February 2025
  • Accept Date: 23 January 2025

Share

How to cite

Statistics